Excess of solid cancers after prasugrel: The food and drug administration outlook

Victor Serebruany, James Floyd, Derek Chew

Research output: Contribution to journalArticle

Abstract

The TRITON-TIMI 38 was a head-to-head trial to assess the efficacy and safety of the experimental antiplatelet agent prasugrel versus standard care with clopidogrel on top of aspirin. Besides some early ischemic protection at the expense of growing over time overwhelming bleeding disadvantage, prasugrel-treated patients experienced significantly higher cancer rates. Recently, the Food and Drug Administration (FDA) issued a Prasugrel Second Review, a detailed 357-page document presenting realistic outlook on various aspects of the TRITON trial including distributions of different cancers between treatment arms. The comprehensive FDA analysis revealed that some preclinical but especially human data overwhelmingly indicate excessive cancer risks after prasugrel. Indeed, despite excellent baseline balance, prasugrel-treated patients experienced extra cancer-related deaths, 27% higher risks for new cancers occurrences, and 36.8% increase of new solid malignant cancers. The FDA report concluded that cancer risks after prasugrel are real, especially high in women, and after 4 months of therapy at least for solid highly metastatic cancers. These unexpected findings may be explained by disruption of tumor-platelet aggregates by chronic profound oral platelet inhibition causing extensive dissemination of initially silent tumors. Since prasugrel gained regulatory approval, the alarming cancer data should be confirmed in further specifically designed trial and carefully assessed in large registries.

Original languageEnglish (US)
JournalAmerican Journal of Therapeutics
DOIs
StateAccepted/In press - Jul 10 2010
Externally publishedYes

Fingerprint

United States Food and Drug Administration
Neoplasms
clopidogrel
Prasugrel Hydrochloride
Blood Platelets
Bleeding Time
Platelet Aggregation Inhibitors
Aspirin
Registries
Safety

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Excess of solid cancers after prasugrel : The food and drug administration outlook. / Serebruany, Victor; Floyd, James; Chew, Derek.

In: American Journal of Therapeutics, 10.07.2010.

Research output: Contribution to journalArticle

@article{257982ef758a4afc899a4a5b1c9da406,
title = "Excess of solid cancers after prasugrel: The food and drug administration outlook",
abstract = "The TRITON-TIMI 38 was a head-to-head trial to assess the efficacy and safety of the experimental antiplatelet agent prasugrel versus standard care with clopidogrel on top of aspirin. Besides some early ischemic protection at the expense of growing over time overwhelming bleeding disadvantage, prasugrel-treated patients experienced significantly higher cancer rates. Recently, the Food and Drug Administration (FDA) issued a Prasugrel Second Review, a detailed 357-page document presenting realistic outlook on various aspects of the TRITON trial including distributions of different cancers between treatment arms. The comprehensive FDA analysis revealed that some preclinical but especially human data overwhelmingly indicate excessive cancer risks after prasugrel. Indeed, despite excellent baseline balance, prasugrel-treated patients experienced extra cancer-related deaths, 27{\%} higher risks for new cancers occurrences, and 36.8{\%} increase of new solid malignant cancers. The FDA report concluded that cancer risks after prasugrel are real, especially high in women, and after 4 months of therapy at least for solid highly metastatic cancers. These unexpected findings may be explained by disruption of tumor-platelet aggregates by chronic profound oral platelet inhibition causing extensive dissemination of initially silent tumors. Since prasugrel gained regulatory approval, the alarming cancer data should be confirmed in further specifically designed trial and carefully assessed in large registries.",
author = "Victor Serebruany and James Floyd and Derek Chew",
year = "2010",
month = "7",
day = "10",
doi = "10.1097/MJT.0b013e3181e9b675",
language = "English (US)",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Excess of solid cancers after prasugrel

T2 - The food and drug administration outlook

AU - Serebruany, Victor

AU - Floyd, James

AU - Chew, Derek

PY - 2010/7/10

Y1 - 2010/7/10

N2 - The TRITON-TIMI 38 was a head-to-head trial to assess the efficacy and safety of the experimental antiplatelet agent prasugrel versus standard care with clopidogrel on top of aspirin. Besides some early ischemic protection at the expense of growing over time overwhelming bleeding disadvantage, prasugrel-treated patients experienced significantly higher cancer rates. Recently, the Food and Drug Administration (FDA) issued a Prasugrel Second Review, a detailed 357-page document presenting realistic outlook on various aspects of the TRITON trial including distributions of different cancers between treatment arms. The comprehensive FDA analysis revealed that some preclinical but especially human data overwhelmingly indicate excessive cancer risks after prasugrel. Indeed, despite excellent baseline balance, prasugrel-treated patients experienced extra cancer-related deaths, 27% higher risks for new cancers occurrences, and 36.8% increase of new solid malignant cancers. The FDA report concluded that cancer risks after prasugrel are real, especially high in women, and after 4 months of therapy at least for solid highly metastatic cancers. These unexpected findings may be explained by disruption of tumor-platelet aggregates by chronic profound oral platelet inhibition causing extensive dissemination of initially silent tumors. Since prasugrel gained regulatory approval, the alarming cancer data should be confirmed in further specifically designed trial and carefully assessed in large registries.

AB - The TRITON-TIMI 38 was a head-to-head trial to assess the efficacy and safety of the experimental antiplatelet agent prasugrel versus standard care with clopidogrel on top of aspirin. Besides some early ischemic protection at the expense of growing over time overwhelming bleeding disadvantage, prasugrel-treated patients experienced significantly higher cancer rates. Recently, the Food and Drug Administration (FDA) issued a Prasugrel Second Review, a detailed 357-page document presenting realistic outlook on various aspects of the TRITON trial including distributions of different cancers between treatment arms. The comprehensive FDA analysis revealed that some preclinical but especially human data overwhelmingly indicate excessive cancer risks after prasugrel. Indeed, despite excellent baseline balance, prasugrel-treated patients experienced extra cancer-related deaths, 27% higher risks for new cancers occurrences, and 36.8% increase of new solid malignant cancers. The FDA report concluded that cancer risks after prasugrel are real, especially high in women, and after 4 months of therapy at least for solid highly metastatic cancers. These unexpected findings may be explained by disruption of tumor-platelet aggregates by chronic profound oral platelet inhibition causing extensive dissemination of initially silent tumors. Since prasugrel gained regulatory approval, the alarming cancer data should be confirmed in further specifically designed trial and carefully assessed in large registries.

UR - http://www.scopus.com/inward/record.url?scp=77954554805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954554805&partnerID=8YFLogxK

U2 - 10.1097/MJT.0b013e3181e9b675

DO - 10.1097/MJT.0b013e3181e9b675

M3 - Article

C2 - 20634669

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

ER -